Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Fujian Cancer Hospital
RemeGen Co., Ltd.
Icahn School of Medicine at Mount Sinai
Fujian Cancer Hospital
Tianjin Medical University Cancer Institute and Hospital
Instituto do Cancer do Estado de São Paulo
Tianjin Medical University Cancer Institute and Hospital
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Athenex, Inc.
Tianjin Medical University Cancer Institute and Hospital
Fudan University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Seoul St. Mary's Hospital
Hallym University Medical Center
Yonsei University
Chengdu Kanghong Biotech Co., Ltd.
China Medical University, China
Affiliated Hospital of Qinghai University
Seoul National University Bundang Hospital
China Medical University, China
Charite University, Berlin, Germany
Fudan University
Jiangsu HengRui Medicine Co., Ltd.
Huashan Hospital
Hanmi Pharmaceutical Company Limited
Hanmi Pharmaceutical Company Limited
Korean Cancer Study Group